mechanism of action of glp 1 agonist GLP-1 Agonists in Cardiovascular Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies Cardiovascular effects of Glucagon-like peptide

A meta-analysis pooling data from two phase II and five phase III trials195 confirmed that tirzepatide elicited greater HbA1c reductions than placebo, GLP-1RAs, and basal insulin

Patients with a personal history of medullary thyroid carcinoma (MTC) should discuss this with their specialist before considering GLP-1 medications

Statements Author contributions DA: Resources, Funding acquisition, Formal analysis, Software, Conceptualization, Methodology, Writing original draft, Investigation, Data curation

[DOI] [PubMed] [Google Scholar] 52.Exton J.H., Park C.R

Although the results look promising and have potential for a positive impact, there is always a chance that a change in medication could make you feel worse